05:08 AM EDT, 06/16/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Sunday that results from a phase 2 trial of its experimental combination of Talvey and Tecvayli showed a nearly 79% overall response rate with durability in patients with a certain type of cancer.

The results cover patients with triple-class exposed relapsed or refractory multiple myeloma who have true extramedullary disease.

The company said that 54% of the patients achieved a complete response or better in the study. Results from responders indicated "deep and durable" responses, the company said.

Treatment with the combination led to 61% of patients progression free and alive at one year, Johnson & Johnson ( JNJ ) said.

Extramedullary disease represents an aggressive form of multiple myeloma.